Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07217483

The Feasibility of Cream for Treatment of Neonatal Hypoglycemia

Prolact CR (cream) is a fat supplement that is derived from pasteurized human donor milk. It has been utilized in babies who are born premature in the neonatal intensive care unit (NICU) setting to improve growth while avoiding cow milk exposure. There is no literature on the use of cream as a treatment for low blood glucose levels in newborns who are at risk. It is known that fat in human colostrum plays a vital role in providing energy, substrate, and stimulates gluconeogenesis. Gluconeogenesis is the process that helps in the sustainment of blood glucose. Dextrose gel that is used to treat low blood glucose levels helps in raising the blood glucose, but does not help in sustainment.

The objective of this pilot study is to evaluate the utility, feasibility, and acceptability of administering cream for the treatment of newborn low blood glucose levels in a couplet care unit. Investigators hypothesized that 3 ml/kg of cream (0.2 g/kg of carbohydrate and 0.75 g/kg of fat), if given in the place of 0.5 ml/kg (0.2 g/kg of carbohydrate) would increase and stabilize the blood glucose levels. Investigators also speculated that newborns would tolerate the cream with no adverse effects, and caregivers (nurses and parents) would find its use feasible and acceptable.

Parents of newborns with risk factors for hypoglycemia [born to mothers with diabetes, small for gestational age, large for gestational age, or late prematurity (35 to 37 weeks' gestation at birth) who intended to breastfeed exclusively will be approached to consent for the study either before or after delivery of the infant. Newborns with major congenital anomalies or those admitted immediately to the NICU after birth will be excluded.

The main questions hoping to answer

1. What percentage of newborns receiving cream for treatment of hypoglycemia will need NICU admission for IV dextrose? 2. How many median doses of cream are needed? 3. What percentage of infants will be discharge exclusively feeding human milk from couplet care unit? 4. What percentage of the surveys will show parent/nursing satisfaction with the product?

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 24 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Baylor Scott & White Medical Center - McKinney

McKinney, Texas, 75071, United States

Location status: Recruiting

Location contact

Arpitha Chiruvolu, MD

SUB_INVESTIGATOR

Karen Stanzo, PhD

CONTACT

[email protected]

469-764-6282

Karen Stanzo, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newborns at risk for hypoglycemia (born to mothers with diabetes, small for gestational age, large for gestational age, late preterm born 35 to 37 weeks gestational age)

Exclusion criteria

  • Newborns with major congenital anomalies
  • Newborns directly admitted to the NICU form delivery room

Treatment and study plan

Prolact CR for hypoglycemia

Dietary Supplement

Utilizing Prolact CR instead of dextrose gel for management of newborn hypoglycemia

Primary outcomes

  1. NICU admission

    Time frame: Birth to hospital discharge at 2 to 5 days of life

    Admission to neonatal intensive care unit for intravenous dextrose for treatment of hypoglycemia

Study contacts

Contact information is provided by the study sponsor or research team.

Arpitha Chiruvolu, MD

CONTACT

[email protected]

Karen Stanzo, PhD

CONTACT

[email protected]

469-764-6282

Sponsors and collaborators

Lead sponsor

Baylor Research Institute

Other

Registry information

Official study title

The Feasibility of Prolacta CR for Treatment of Neonatal Hypoglycemia

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 16, 2025
Registry last updated
Oct 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.